イスラエルで最高の子宮癌医師 - トップ15名の医師

メリムスキー教授は、軟部組織および骨腫瘍学の第一人者であり、スーラスキー医療センターにおける肉腫治療に革新をもたらしました。

• 肉腫治療を専門とした41年の経験以上の経験
• パリのギュスターブ・ルシー研究所にてフェローシップ研修を修了
• 軟部組織および骨肉腫におけるESMOファカルティのメンバー
• 整形外科腫瘍学に関する広範な研究を発表

Dr. Shira Felder is a senior radiation oncologist. She focuses on gynecologic and urologic cancers. She has advanced expertise in VMAT, IMRT, SBRT, and gynecologic brachytherapy. She delivers precise treatment with fewer side effects.

She heads the Gynecologic Oncology Service at Sheba Medical Center. She is a senior physician in the Radiation Oncology Division. She earned her MD at Hadassah. She completed residency at Sheba and a fellowship in the Radiation Medicine Program at the University of Toronto and Princess Margaret Cancer Centre. She is board-certified in Radiation Oncology. She is a member of ESTRO, the Israeli oncology societies, the CPSO, and the CMA.

Her research covers brachytherapy patient safety. It also includes stereotactic ablative radiotherapy for stage I lung cancer. She has studied treatment delays in cervical cancer. She has examined vitamin D deficiency in oncology patients.

Professor Dan Grisaro is a leading Israeli specialist in gynecological cancer diagnosis and treatment, specializing in ovarian cancer, uterine cancer, and cervical cancer. He has senior physician, head of department and lecturer experience at various medical centers and universities. He has held 39 presentations and is the author of 83 published scientific articles, and is a member of various professional societies.

Dr. Irina Stepfansky is an oncologist and internal medicine specialist at Sourasky Medical Center. She has more than 25 years of clinical experience. Since 2015, she has directed the Oncology Hospitalization department. Dr. Stepfansky earned her medical degree from Grodno University in Belarus. She completed advanced oncology training at Tel Aviv Medical Center.

Dr. Stepfansky has been licensed in Israel since 2000. She has led and participated in many phase I-III oncology clinical trials. Her work has helped improve cancer care and patient outcomes. She is recognized for her expertise in both internal medicine and oncology. Dr. Stepfansky has a strong record in research and clinical leadership.

Education/Residency:

• Completed residency in general oncology and radiotherapy (radiation therapy) at Sheba Hospital, Tel Hashomer.
• During her work, she gained extensive experience in treating tumors of the female reproductive system and is currently a coordinator for the treatment of patients suffering from these diseases.
• Fellowship - Anderson Cancer Center, Houston, Texas - 2012-2014

Dr. Tatyana Rabin's research interests include:

Methods of destruction of malignant neoplasms by heating with the help of ultrasonic waves, research into the use of brachytherapy in the treatment of oncogynecological diseases,

study of the mechanisms of response at the molecular level of prostate tumor cells to radiotherapy;

clinical studies of oncomammology, oncopulmonology, ocular lymphoma.

Dr. Rabin is investigating the molecular mechanisms by which prostate cancer cells respond to radiation therapy. This research is being conducted in collaboration with the Weizmann Institute of Science.

In addition, Dr. Rabin has been involved in clinical research in the areas of breast cancer, lung cancer, and ocular lymphoma.

Dr. Rabin is currently coordinating a new and unique study at Sheba Hospital that is investigating a method of treating cancerous tumors using MRI-guided ultrasound waves. This method involves raising the tumor's temperature to a certain level and then destroying it.

Awards:

Dr. Tatyana Rabin was recognized as the best hospital employee for 2007.

Experience and participation in scientific research:

• Scientific research in the field of gynecological oncology
• Scientific research in the field of lung tumors
• Application of brachytherapy in oncogynecology
• SBRT techniques in the treatment of tumors of the respiratory system
• Study of molecular mechanisms of prostate tumor cell response to radiation therapy. This study was organized in collaboration with the laboratory of the H. Weizmann Institute.
• In addition, Dr. Rabin has been involved in clinical research in the areas of breast cancer, lung cancer, and ocular lymphoma.

Membership in medical societies :

• Israel Society of Oncology and Clinical Radiotherapy (ISCORT) American Society of Radiology and Oncology (ASTRO)
• Israel Association of Palliative Medicine

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Oncogynecologist. Specialist in minimally invasive surgeries

Radiotherapist

Specialist in Obstetrics, Gynecology and Oncogynecology

Gynecologist, Specialist in endoscopic and laparoscopic operations

Dr. Tamar Jablonski-Perec is an oncologist at Hadassah Medical Center in Jerusalem. She holds a Doctor of Medical Sciences from the Hebrew University and has experience from the renowned Sloan-Kettering Cancer Center in New York. She is the Head of Institute of Oncology, Head of Breast Cancer Treatment Center, and Professor of the Department of Oncology at the Hebrew University. She is a member of several international cancer communities and was awarded a scholarship from the Hadassah Medical School.